Now Reading
BioNTech Founders Believe Cancer Vaccine Will Be Ready by 2030

BioNTech Founders Believe Cancer Vaccine Will Be Ready by 2030

Researchers say that a cure for cancer is still on its way, but in the meantime, a cancer vaccine could be the key to preventing cancer from a patient.

The couple behind the Pfizer/BioNTech Covid-19 vaccine have been hard at work studying cancer and hope to develop both a cure and preventative measures.

“We feel that a cure for cancer or to changing cancer patients’ lives is in our grasp,” professor Ozlem Tureci told BBC News. Her husband Dr. Ugur Sahin said he thought cancer vaccines could be widely available “before 2030.”

The husband-and-wife duo founded research company BioNTech in 2008 originally to develop and produce treatments for individualized cancer immunotherapy, using mRNA technology. In 2020, when the pandemic hit, they quickly adapted their resources and technology to create one of the Covid-19 vaccines.

Tureci and Sahin explained that their work on developing the Pfizer vaccine could help accelerate their work on a cancer vaccine not that mRNA technology is widely used.

“The development of several COVID vaccines in record time showed the possibilities of mRNA vaccine technology, which could one day become an effective treatment to help beat cancer,” said Dr. Sam Godfrey, research information lead at Cancer Research U.K. “Just as science was our route out of the pandemic, science is our route to beating cancer. We’re optimistic that, in the future, we will see mRNA technology and other exciting vaccine approaches giving doctors more treatment options to help beat cancer.

There’s still a long, long way to go before this is officially on the market. For one, it will take time to develop a vaccine for all types of cancer, and researchers are still working to determine what makes someone susceptible to cancer in the first place. But scientists are optimistic, and one day — hopefully soon — cancer will become a thing of the past.

View Comments (0)

Leave a Reply

© 2023 RELEVANT Media Group, Inc. All Rights Reserved.

Scroll To Top

You’re reading our ad-supported experience

For our premium ad-free experience, including exclusive podcasts, issues and more, subscribe to

Plans start as low as $2.50/mo